Return to homepagePandemic Pact

SARS-CoV2 ASO: RNA antisense oligonucleotide therapy targeting SARS-CoV-2 replication and transcription

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    ANR

  • Principal Investigator

    Eric Barrey

  • Research Location

    France

  • Lead Research Institution

    Génétique Animale et Biologie Intégrative (GABI) - Inrae / Jouy-en-Josas

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The SARS-CoV2 ASO project, coordinated by Eric Barrey (UMR 1313 - Animal Genetics and Integrative Biology (GABI) - Inrae / Jouy-en-Josas), aims to demonstrate the anti-viral activity of antisense oligonucleotides (ASO ) directed against the replication of the SARS-CoV-2 virus on an in vitro model of infection of Vero E6 cells in culture, then to test the best treatment on a validated animal model to demonstrate the in vivo efficacy of the best candidate ASOs in order to to perform a preclinical trial.